Baby hamster kidney cell–derived recombinant factor VIII: a quarter century of learning and clinical experience

Inhibitors in haemophilia A: a perspective on clotting factor products as a potential contributing factor

(2016) P. Mathew et al.   HAEMOPHILIA

Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial

(2016) K. Saxena et al.   HAEMOPHILIA

A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A

(2016) Flora Peyvandi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia A

(2016) Midori Shima et al.   NEW ENGLAND JOURNAL OF MEDICINE

Changing Paradigm of Hemophilia Management: Extended Half-Life Factor Concentrates and Gene Therapy

(2016) Amy Dunn et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Practical considerations in choosing a factor VIII prophylaxis regimen: Role of clinical phenotype and trough levels

(2016) R. Ljung et al.   THROMBOSIS AND HAEMOSTASIS

Manufacturing process used to produce long-acting recombinant factor VIII Fc fusion protein

(2015) Justin McCue et al.   BIOLOGICALS

BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial

(2015) R. Ljung et al.   HAEMOPHILIA

Turoctocog alfa (recombinant factor VIII)

(2015) A. Tiede et al.   Hamostaseologie

Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)

(2015) K. Kavakli et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial

(2015) P. Chowdary et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Factor VIII Is Synthesized in Human Endothelial Cells, Packaged in Weibel-Palade Bodies and Secreted Bound to ULVWF Strings

(2015) Nancy A. Turner et al.   PLoS One

Development, upscaling and validation of the purification process for human-cl rhFVIII (Nuwiq®), a new generation recombinant factor VIII produced in a human cell-line

(2015) Stefan Winge et al.   PROTEIN EXPRESSION AND PURIFICATION

Assessment of Clotting Factor Concentrates—Pivotal Studies and Long-Term Requirements

(2015) Flora Peyvandi et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Inhibitor development in haemophilia according to concentrate

(2015) Riita Lassila et al.   THROMBOSIS AND HAEMOSTASIS

Individualizing prophylaxis in hemophilia: a review

(2015) Pia Petrini et al.   Expert Review of Hematology

Murine coagulation factor VIII is synthesized in endothelial cells

(2014) L. A. Everett et al.   BLOOD

Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A

(2014) T. Calvez et al.   BLOOD

Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011

(2014) P. W. Collins et al.   BLOOD

Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010

(2014) C. Vézina et al.   HAEMOPHILIA

Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A

(2014) T. E. Coyle et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia

(2013) Amy Shapiro   EXPERT OPINION ON BIOLOGICAL THERAPY

Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART)

(2013) M. J. Manco-Johnson et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Human liver sinusoidal endothelial cells but not hepatocytes contain factor VIII

(2013) T. Shahani et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Factor VIII Products and Inhibitor Development in Severe Hemophilia A

(2013) Samantha C. Gouw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systematic Review of the Role of FVIII Concentrates in Inhibitor Development in Previously Untreated Patients with Severe Hemophilia A: A 2013 Update

(2013) Antonio Coppola et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII

(2013) Sabine B. Zollner et al.   THROMBOSIS RESEARCH

Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation

(2012) Darius Ghaderi et al.   Biotechnology & Genetic Engineering Reviews

Standards and monitoring treatment

(2012) T. W. BARROWCLIFFE et al.   HAEMOPHILIA

Management of bleeding disorders in the elderly

(2012) R. KRUSE-JARRES et al.   HAEMOPHILIA

Guidelines for the management of hemophilia

(2012) A. Srivastava et al.   HAEMOPHILIA

Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII

(2012) Christoph Kannicht et al.   THROMBOSIS RESEARCH

A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)

(2011) A. GRINGERI et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia

(2010) A. PEDEN et al.   HAEMOPHILIA

Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia

(2009) U. MARTINOWITZ et al.   HAEMOPHILIA

Cumulative analysis of inhibitor formation in patients with haemophilia A treated with sucrose-formulated recombinant factor VIII

(2009) N. BAJWA et al.   HAEMOPHILIA

Efficacy and safety evaluation of sucrose-formulated recombinant factor VIII for Taiwanese patients with haemophilia A

(2009) J.-H. YOUNG et al.   HAEMOPHILIA

Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study

(2009) P. COLLINS et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders

(2008) D. KEELING et al.   HAEMOPHILIA